Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anne M Hassell

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Journal of Medicinal Chemistry|June 5, 2008
X-ray crystal structure of the novel enhanced-affinity glucocorticoid agonist fluticasone furoate in the glucocorticoid receptor-ligand binding domainKeith Biggadike, Randy K Bledsoe, Anne M Hassell, et al.
Bioorganic & Medicinal Chemistry Letters|March 23, 2005
Novel and potent cyclic cyanamide-based cathepsin K inhibitorsDavid N Deaton, Anne M Hassell, Robert B McFadyen, et al.
Bioorganic & Medicinal Chemistry Letters|May 18, 2005
Acyclic cyanamide-based inhibitors of cathepsin KDavid G Barrett, David N Deaton, Anne M Hassell, et al.
Bioorganic & Medicinal Chemistry Letters|June 5, 2004
Exploration of the P2-P3 SAR of aldehyde cathepsin K inhibitorsEric E Boros, David N Deaton, Anne M Hassell, et al.
Bioorganic & Medicinal Chemistry Letters|April 28, 2009
Discovery of 3,5-disubstituted-1H-pyrrolo[2,3-b]pyridines as potent inhibitors of the insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinaseSamarjit Patnaik, Kirk L Stevens, Roseanne Gerding, et al.
Bioorganic & Medicinal Chemistry Letters|September 3, 2004
Potent and selective P2-P3 ketoamide inhibitors of cathepsin K with good pharmacokinetic properties via favorable P1', P1, and/or P3 substitutionsDavid G Barrett, John G Catalano, David N Deaton, et al.
Bioorganic & Medicinal Chemistry Letters|October 7, 2008
Synthesis and evaluation of pyrazolo[1,5-b]pyridazines as selective cyclin dependent kinase inhibitorsKirk L Stevens, Michael J Reno, Jennifer B Alberti, et al.
Journal of Medicinal Chemistry|January 23, 2004
Design of potent, selective, and orally bioavailable inhibitors of cysteine protease cathepsin kFrancis X Tavares, Virginia Boncek, David N Deaton, et al.
Bioorganic & Medicinal Chemistry Letters|December 27, 2005
Novel, potent P2-P3 pyrrolidine derivatives of ketoamide-based cathepsin K inhibitorsDavid G Barrett, John G Catalano, David N Deaton, et al.
Bioorganic & Medicinal Chemistry Letters|November 18, 2005
Semicarbazone-based inhibitors of cathepsin K, are they prodrugs for aldehyde inhibitors?Kim K Adkison, David G Barrett, David N Deaton, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Journal of Medicinal Chemistry|June 5, 2008
X-ray crystal structure of the novel enhanced-affinity glucocorticoid agonist fluticasone furoate in the glucocorticoid receptor-ligand binding domainKeith Biggadike, Randy K Bledsoe, Anne M Hassell, et al.
Bioorganic & Medicinal Chemistry Letters|March 23, 2005
Novel and potent cyclic cyanamide-based cathepsin K inhibitorsDavid N Deaton, Anne M Hassell, Robert B McFadyen, et al.
Bioorganic & Medicinal Chemistry Letters|May 18, 2005
Acyclic cyanamide-based inhibitors of cathepsin KDavid G Barrett, David N Deaton, Anne M Hassell, et al.
Bioorganic & Medicinal Chemistry Letters|June 5, 2004
Exploration of the P2-P3 SAR of aldehyde cathepsin K inhibitorsEric E Boros, David N Deaton, Anne M Hassell, et al.
Bioorganic & Medicinal Chemistry Letters|April 28, 2009
Discovery of 3,5-disubstituted-1H-pyrrolo[2,3-b]pyridines as potent inhibitors of the insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinaseSamarjit Patnaik, Kirk L Stevens, Roseanne Gerding, et al.
Bioorganic & Medicinal Chemistry Letters|September 3, 2004
Potent and selective P2-P3 ketoamide inhibitors of cathepsin K with good pharmacokinetic properties via favorable P1', P1, and/or P3 substitutionsDavid G Barrett, John G Catalano, David N Deaton, et al.
Bioorganic & Medicinal Chemistry Letters|October 7, 2008
Synthesis and evaluation of pyrazolo[1,5-b]pyridazines as selective cyclin dependent kinase inhibitorsKirk L Stevens, Michael J Reno, Jennifer B Alberti, et al.
Journal of Medicinal Chemistry|January 23, 2004
Design of potent, selective, and orally bioavailable inhibitors of cysteine protease cathepsin kFrancis X Tavares, Virginia Boncek, David N Deaton, et al.
Bioorganic & Medicinal Chemistry Letters|December 27, 2005
Novel, potent P2-P3 pyrrolidine derivatives of ketoamide-based cathepsin K inhibitorsDavid G Barrett, John G Catalano, David N Deaton, et al.
Bioorganic & Medicinal Chemistry Letters|November 18, 2005
Semicarbazone-based inhibitors of cathepsin K, are they prodrugs for aldehyde inhibitors?Kim K Adkison, David G Barrett, David N Deaton, et al.
Pageof 2